Onsdag 30 Oktober | 09:25:25 Europe / Stockholm
Svenska | English

Nanexa

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-19 08:00 Bokslutskommuniké 2024
2024-11-07 08:00 Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-20 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - Årsstämma
2023-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-10 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2022-06-09 - Årsstämma
2022-04-20 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-06-12 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-12 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-10-23 - Extra Bolagsstämma 2017
2017-08-24 - Kvartalsrapport 2017-Q2
2017-06-13 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 - Årsstämma
2017-05-17 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-27 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-06 - Extra Bolagsstämma 2016
2016-02-25 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad plattform som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla nya produkter. Nanexa har samarbete med flertalet läkemedelsbolag, huvudsakligen runtom den nordiska marknaden.
Nanexa publishes interim report for January-March 2024
2024-05-03 08:00:00

NEX-22 clinical trial preparations ongoing and Novo Nordisk collaboration progressing well

Significant events during the first quarter 2024

  • No significant event during the quarter.

Significant events after the end of the period

  • Nanexa announced that in the ongoing review process of the clinical trial application for the phase I study with NEX-22, additional supplements have been requested from the German Medicines Agency, which in the new European regulatory process takes more time than expected. The company estimates that it can obtain approval and start the study towards the end of the second quarter of 2024.

Financial overview

1 January - 31 March 2024

  • Turnover amounted to: TSEK 7,754 (8,173)
  • Operating profit (EBIT) amounted to: TSEK -3,363 (-8,703)
  • Profit after tax amounted to: TSEK -2,823 (-8,603)
  • Earnings per share amounted to: SEK -0.02 (-0.14)
  • Cash flow for the period amounted to: TSEK -17,328 (-20,682)
  • Cash and cash equivalents at end of period: TSEK 47,839 (60,500)

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/.

Report commentary, May 3 at 12:00 CET

A live commentary with CEO David Westberg will take place on May 3 at 12:00 noon via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat. The presentation will be held in Swedish.

The report commentary will be available via this link.

The report commentary will also be published on Nanexa's website afterwards.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-03 08:00 CEST.

Attachments

Nanexa Interim Report Jan Mar 2024

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden